COPD and environmental impact: cardiopulmonary risk after an exacerbation, prompt escalation and the inhaler’s carbon footprint

Speaker

Respiratory and sleep physician, Gold Coast (name unclear on the recording) — introduced as having trained extensively in Australia and India, having headed respiratory and sleep medicine services at large tertiary-care hospitals in India, with awards for clinical work and community initiatives, and with rooms at “Pacific private clinic” (as captured by ASR). He mentions extensive work in Delhi and describes the Gold Coast as “the capital of the retirees”.

Host

Meeting chair (name not captured) who closes with the night’s key takeaways.

Session context

Otter title COPD and Environmental Impact · id ddciJSThZ2CQWha3WDoO8xaXtRE · ~23 min, recorded 11 March 2026 8:02 pm AEST — the same evening as the UK speaker’s COPD management strategies webinar. He presents as a recap, “emphasising some of the points” made earlier. Speakers are labelled only Speaker 1–6. Name note: Otter’s summary calls the presenter “Professor Kotha”; the only place that name appears in the transcript is when he refers to points another professor made earlier, so it is almost certainly an ASR error and is not used here. Sponsor note: no sponsor statement was captured, but the talk centres on one AstraZeneca product (budesonide/glycopyrronium/formoterol, Breztri Aerosphere — ASR “breast tree”, “Breast three heterosphere”), and he compliments AstraZeneca (ASR “as to Seneca”) for bringing the environmental angle into the evening. Treat it as a possibly sponsored, product-focused session.

Key messages for GPs

• Think about the environment, not only the patient in front of you. Propellant-based metered-dose inhalers add to respiratory care’s carbon footprint — and so does every ED visit, admission and ICU stay.
• “A good, controlled patient is not only good for the healthcare system, good for his own health, but also for the environment.” Better control is the biggest green lever.
• An exacerbation is the central event in COPD. Each one is a step down that the patient may not climb back from, and the next one tends to come sooner.
• Cardiopulmonary risk: COPD exacerbations are followed by a rise in heart attack, stroke, heart-failure decompensation, arrhythmia and death — highest in the days and months straight after the event.
• Hospitals stabilise; GPs often have to make the plan. Many patients leave ED without a follow-up plan or with no change in treatment.
• Escalate promptly when guideline criteria are met — he quoted about a 34% reduction in subsequent severe exacerbations when triple therapy was started promptly, with less benefit the longer it was delayed.
• Match the device to the patient: dexterity, inspiratory flow, coordination and spacer use matter more than any single product claim.

The environmental angle in respiratory care

He opened with something that “doesn’t really come to mind” in a busy clinic: the CO₂ and sustainability cost of the care we give. We think about sustainability at home — which bags we use — but in clinic the sole focus is doing “whatever it takes” for the patient sitting in front of us. He suggested adding the environment to that picture.

• Why respiratory physicians care. He described working extensively in Delhi and said the environment was a major driver for him. Australia, with its wide climatic swings, is also very vulnerable. Respiratory medicine, he argued, “should be leading this change, because we see the impact.”
• Propellants. Metered-dose inhalers use a propellant that has had a major environmental impact. Propellants have “gone through a transition” and there are different HFA propellants, but whichever is used, it adds to environmental impact.
• Healthcare use is itself a footprint. More healthcare use — ED, ICU and other resources — increases environmental impact overall. So look for every point of care where impact can be reduced.
• Plastic and single-use devices. Someone in the room raised how much plastic goes into a single inhaler that is used once and thrown away. He agreed it was a fair point and said the healthcare industry is “slowly” rising to the challenge.

COPD and cardiopulmonary risk

Look at what is filling hospital beds, he said, and COPD is “a big giant”. Dig into what drives the extra illness and death and much of it is cardiovascular. Cardiology has done well at recognising, organising and treating cardiovascular risk; in COPD “we just got to get better” at exploring those risks.

He defined cardiopulmonary risk as the combined risk of:

• myocardial infarction / acute coronary syndrome
• stroke
• heart-failure decompensation
• arrhythmias
• death from any of these, and from COPD itself.

Figures he quoted (as captured by the transcript):

Transcript caveat: these numbers come from slides he said the audience had “seen earlier in the evening”; the slide text was not captured and several figures are muddled by the ASR. Check primary sources before quoting them to patients or colleagues.

Exacerbations: the step-down and the “spring”

He called an exacerbation “the central event in the journey of a patient of COPD … It changes everything.” Two images stood out:

1. A step-ladder pattern. After a major exacerbation the patient drops down a step and has to try to climb back. Each exacerbation is a loss.
2. A spring. Each exacerbation brings the next one sooner, so the rate of severe exacerbations rises with each event.

After discharge: the GP’s window

He quoted that about 25% of patients are not prescribed treatment immediately after discharge and said he sees this “unfortunately” every day: busy EDs stabilise and discharge patients “without a proper sort of a follow-up plan”, leaving it to GPs to create one. With current healthcare pressures, hospitals increasingly “just stabilise the patient” and the plan falls to community care.

Plotting heart risk against lung risk

He showed a chart he said had been recommended by about 100 international experts. It plots two axes:

• Cardiovascular risk — from risk factors through established cardiovascular disease to a recent cardiovascular event.
• COPD severity — using the CAT score (COPD Assessment Test; ASR “CAD score”) and exacerbation history.

Patients high on both axes are “the most vulnerable” and need all the attention and interventions available. The practical habit: in patients with significant heart disease, ask about COPD; in patients with significant COPD, assess cardiovascular risk.

GOLD and COPD-X: the treatment steps

He summarised GOLD (the Global Initiative for Chronic Obstructive Lung Disease, an international consensus guideline updated every year) and Australia’s COPD-X guidelines as he presented them:

Transcript caveat: the ASR is muddled here (“lava or Lama”, “blood disputers”, “invariant corticosterone”); the table reflects the most likely meaning. Always check the current GOLD report, the Lung Foundation Australia COPD-X guidelines and PBS criteria.

Single-inhaler triple therapy: what he reported

He described Breztri Aerosphere as a triple combination (budesonide/glycopyrronium/formoterol) in a pressurised metered-dose inhaler (pMDI) for moderate to severe COPD, taken as two puffs twice a day. It has been available “for a few years” and he said many GPs will already have patients on it.

The trial name was not stated in this part of the transcript. See the companion post for the UK speaker’s more detailed run-through of the trial evidence. Product claims in a possibly sponsored session should be weighed with care.

Don’t delay escalation

Echoing an earlier speaker (ASR “Mark Moyer” — apparently the UK speaker from the companion talk), he stressed that escalation should not be delayed once a patient qualifies:

• With prompt initiation after an exacerbation, he quoted almost a 34% reduction in subsequent severe exacerbations.
• If initiation is delayed, there is still some benefit, but it is smaller.
• Prompt initiation also improved (lengthened) the time to the next severe exacerbation (the ASR says “reduced”; the context suggests a better outcome).
• “There’s no reason why, in an advanced healthcare system like ours, these patients should be delayed.”

Deposition, propellants and choosing a device

Lung deposition

He was careful to say there are no head-to-head clinical trials between the triple inhalers. Lung-deposition studies suggested good, even deposition in small and large airways, captured as “1.8 times” one comparator (ASR “the trilogy”, likely Trelegy) and “almost one and a half times” another (comparator garbled). He said this held in patients with reduced inspiratory flow — common in breathless patients — and put it down to particle size, aerosol dynamics and the propellant-based Aerosphere technology: the propellant’s job is to improve deposition. Later he acknowledged that deposition findings have not been shown to translate into clinical outcomes.

Propellant-free options

Asked whether any new technology avoids damaging propellants, he pointed to dry powder inhalers (DPIs) (ASR “MPIs”), which use no propellant. The limit is which medicines can be made in powder form.

Q&A highlights

Why that dose?

The question was largely inaudible (it seems to ask whether the dose could be reduced). He said the dose was chosen through phase 2 and phase 3 dose-finding trials as the one giving the best clinical effect.

Can the components be combined differently?

He said combining three drugs into one inhaler is “extremely hard”, and that the manufacturer took a long time to develop the technology. Particle size matters: make the particles larger and deposition goes down. He said another triple pMDI (ASR “Trimble”, apparently Trimbow) has to be kept in the fridge to keep its solution consistent (as stated — check the product information for storage details).

MDI or dry powder for my patient?

Does better deposition mean better outcomes?

He acknowledged that deposition studies have not been matched by clinical-outcome studies; the work on particle size has not always translated into proven clinical benefit (the end of this answer is fragmented on the ASR).

The chair’s takeaways

1. Early and accurate diagnosis of COPD.
2. Guideline-directed therapy.
3. The relationship between COPD and cardiovascular disease, and the definition of cardiopulmonary risk.
4. “Every touch is an opportunity for optimisation.”

GP clinic checklist

1. Treat any COPD exacerbation — including an ED visit with a “stabilised and discharged” outcome — as a heart-and-lung risk event. Aim to review soon after, ideally within the first week.
2. At that review, check whether treatment was changed and whether a follow-up plan exists; if not, make one.
3. Count and code exacerbations (moderate and severe). Check blood eosinophils.
4. Step up therapy promptly when COPD-X / GOLD and PBS criteria are met (e.g. one severe or two moderate exacerbations; eosinophils ≥300 cells/µL favour an inhaled steroid) — don’t wait months.
5. Use reliever use and CAT score as everyday markers of control.
6. Assess cardiovascular risk in every COPD patient — especially those with a productive cough or recent exacerbations — and ask about COPD symptoms in patients with heart disease.
7. Match the device to the patient: inspiratory flow (for DPIs), hand function and dexterity, coordination, spacer use. Check technique every visit.
8. Where a propellant-free device suits the patient equally well, consider it; never compromise control for the footprint — good control is itself the greenest option.
9. Watch for inhaled-steroid side effects, including pneumonia and throat irritation.

Transcript caveats

allcpd.drkotha.com · directory